Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia

Arch Ophthalmol. 1996 Oct;114(10):1261-4. doi: 10.1001/archopht.1996.01100140461020.


A patient who had primary acquired melanosis with marked atypia shown on histological studies received topical 0.02% mitomycin C for 2 weeks and 0.04% mitomycin C for an additional 2 weeks. Conjunctival biopsy specimens were obtained to evaluate the efficacy of the treatment. After the first course of mitomycin C administration, some decrease of conjunctival pigmentation was seen, and histological studies disclosed a lower degree of atypia. After the second application of mitomycin C, the pigmentation disappeared except for one small spot that contained only a few typical melanocytes on histological study. The clinical findings did not change during 7 months of follow-up. No adverse reactions to topical mitomycin C occurred except for mild conjunctival hyperemia at the end of the courses of treatment. Administration of topical mitomycin C may be an effective medical treatment for primary acquired melanosis with atypia.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / therapeutic use*
  • Biopsy
  • Conjunctiva / pathology
  • Conjunctival Diseases / drug therapy*
  • Conjunctival Diseases / etiology
  • Conjunctival Diseases / pathology
  • Female
  • Humans
  • Melanosis / drug therapy*
  • Melanosis / etiology
  • Melanosis / pathology
  • Middle Aged
  • Mitomycin / administration & dosage
  • Mitomycin / therapeutic use*
  • Ophthalmic Solutions


  • Antibiotics, Antineoplastic
  • Ophthalmic Solutions
  • Mitomycin